MX2015014751A - Composiciones y metodos para el tratamiento de la inmunodeficiencia. - Google Patents

Composiciones y metodos para el tratamiento de la inmunodeficiencia.

Info

Publication number
MX2015014751A
MX2015014751A MX2015014751A MX2015014751A MX2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treatment
immunodeficiency
preparing
Prior art date
Application number
MX2015014751A
Other languages
English (en)
Other versions
MX370191B (es
Inventor
S Grossman Adam
B Grossman Jerrold
Mond James
A Goldstein Dov
Original Assignee
Adma Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adma Biologics Inc filed Critical Adma Biologics Inc
Publication of MX2015014751A publication Critical patent/MX2015014751A/es
Publication of MX370191B publication Critical patent/MX370191B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1285—Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos para el tratamiento de la inmunodeficiencia (por ejemplo, enfermedad por inmunodeficiencia primaria). En particular, la invención proporciona composiciones de inmunoglobulina de plasma humano que contienen títulos de anticuerpos seleccionados, específicos para una pluralidad de patógenos respiratorios, métodos de identificación de donadores humanos y muestras de donador para usarse en las composiciones, métodos de preparación de las composiciones, y métodos de utilización de las composiciones (por ejemplo, para la administración profiláctica y/o tratamiento terapéutico (por ejemplo, inmunización pasiva (por ejemplo, profilaxis inmune))).
MX2015014751A 2014-10-28 2015-10-21 Composiciones y su uso en el tratamiento de la inmunodeficiencia. MX370191B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462069589P 2014-10-28 2014-10-28
US14/592,721 US9107906B1 (en) 2014-10-28 2015-01-08 Compositions and methods for the treatment of immunodeficiency
US14/592,727 US9815886B2 (en) 2014-10-28 2015-01-08 Compositions and methods for the treatment of immunodeficiency
US14/790,872 US9714283B2 (en) 2014-10-28 2015-07-02 Compositions and methods for the treatment of immunodeficiency

Publications (2)

Publication Number Publication Date
MX2015014751A true MX2015014751A (es) 2016-10-19
MX370191B MX370191B (es) 2019-12-04

Family

ID=53785845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014751A MX370191B (es) 2014-10-28 2015-10-21 Composiciones y su uso en el tratamiento de la inmunodeficiencia.

Country Status (11)

Country Link
US (8) US9107906B1 (es)
EP (2) EP4233903A3 (es)
AU (2) AU2015246157B2 (es)
BR (1) BR102015027387A2 (es)
CA (1) CA2910491C (es)
HK (1) HK1225397A1 (es)
IL (2) IL242156B (es)
MX (1) MX370191B (es)
RU (1) RU2724058C2 (es)
WO (1) WO2016069693A1 (es)
ZA (1) ZA201707303B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014006175B1 (pt) * 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN105601736B (zh) * 2016-01-28 2019-04-23 哈尔滨派斯菲科生物制药股份有限公司 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法
CN106119210B (zh) * 2016-07-01 2019-06-11 中国食品药品检定研究院 一种脊髓灰质炎ⅰ型病毒单克隆抗体及其应用
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US20200246449A1 (en) * 2017-05-03 2020-08-06 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
BR112020013381A2 (pt) * 2018-01-05 2020-12-01 Network Immunology Inc. combinação de imunoglobulina de plasma e imunoglobulina específica ao antigênio para a modificação do sistema imunológico e o tratamento ou prevenção de doenças alérgicas
CA3104603A1 (en) * 2018-06-21 2019-12-26 Emergent Biosolutions Canada Inc. Zika neutralizing antibody compositions and methods of using the same
WO2020097528A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
US11129878B1 (en) * 2020-03-24 2021-09-28 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses
MX2022012509A (es) * 2020-04-06 2022-11-07 Abbott Lab Formulaciones nutricionales para modular citocinas inducidas por la respiracion.
US20220034885A1 (en) * 2020-08-03 2022-02-03 Adma Biologics, Inc. Compositions and methods for determining coronavirus neutralization titers
WO2022060976A1 (en) * 2020-09-17 2022-03-24 The Broad Institute, Inc. Methods for treating infections
CN113943836B (zh) * 2021-11-16 2023-09-22 圣湘生物科技股份有限公司 检测引起呼吸道感染的病原体并鉴定病原体种类的组合物、试剂盒、方法及用途

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021540A (en) 1975-07-28 1977-05-03 Ortho Diagnostics Inc. Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material
JPS5341420A (en) 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
JPS604422B2 (ja) 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
US4174388A (en) 1977-02-14 1979-11-13 Merck & Co., Inc. Method for preparing hepatitis B immune globulin
US4305870A (en) 1979-01-31 1981-12-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Intravenous plasma derivatives and their production
JPS55124719A (en) 1979-03-22 1980-09-26 Kowa Co Preparation of immune globulin administrable by intravenous injection
FR2460139A1 (fr) 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
US4346073A (en) 1980-04-11 1982-08-24 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis B immune globulin used to inactivate hepatitis B virus in injectable biological products
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4587121A (en) 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
CA1247527A (en) 1983-06-14 1988-12-28 Michael S. Collins High titer pseudomonas immune serum globulin
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
CA1340372C (en) 1984-07-09 1999-02-02 John D. Clements Production of e. coli lt-b enterotoxin subunit
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
SE8501550L (sv) 1985-03-28 1986-09-29 Almex Ab Sett att kontrollera en biljetts ekthet och biljett for att genomfora settet
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4665159A (en) 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717564A (en) 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
FR2605657A1 (fr) 1986-10-22 1988-04-29 Soletanche Procede pour la realisation d'un pieu dans le sol, machine de forage et dispositif pour la mise en oeuvre de ce procede
JP2921574B2 (ja) 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
DE3904415C1 (es) 1989-02-14 1990-04-26 Intracon Handelsgesellschaft Fuer Industriebedarf M.B.H., 6200 Wiesbaden, De
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
WO1991012819A1 (en) 1990-03-02 1991-09-05 Alberta Research Council Improved immunogenic compositions
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
FI933580L (fi) 1991-02-15 1993-10-13 Uab Research Foundation Strukturgen av pneumokockprotein
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5679768A (en) 1991-02-15 1997-10-21 Uab Research Foundation Epitopic regions of pneumococcal surface protein A
US5965141A (en) 1991-02-15 1999-10-12 Uab Research Foundation Epitopic regions of pneumococcal surface protein a
EP0581882B1 (en) 1991-04-22 1998-01-07 Massachusetts Health Research Institute, Inc. (Mhri) Process of screening plasma samples for effective antibody titers against respiratory viruses
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
WO1993015758A1 (en) 1992-02-06 1993-08-19 Abbott Laboratories Composition and method of immunization with improved carrier and hapten-carrier vaccines
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5891438A (en) 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
CA2116261A1 (en) 1993-04-20 1994-10-21 David E. Briles Epitopic regions of pneumococcal surface protein a
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
AU1090895A (en) 1993-11-10 1995-05-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Cytokines from natural killer or t cells
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
EP0831894A1 (en) 1995-06-07 1998-04-01 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
WO1997020940A1 (en) 1995-12-06 1997-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
ITPN960013A1 (it) 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
CN1241937A (zh) 1996-11-22 2000-01-19 普罗克特和甘保尔公司 化妆品组合物
PT848011E (pt) 1996-12-16 2001-08-30 Staat Nl Verteg Door Min Welzi Metodo para acoplar polisacaridos a proteinas
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
KR19980067137A (ko) 1997-01-31 1998-10-15 박원훈 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP0969873B1 (en) 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
ES2230687T3 (es) 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CN1200730C (zh) 1998-02-12 2005-05-11 惠氏控股有限公司 用白细胞介素－12配制的肺炎球菌和脑膜炎球菌疫苗
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
WO1999047168A2 (en) 1998-03-16 1999-09-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
PT1137789E (pt) 1998-12-09 2010-10-21 Phyton Holdings Llc Um método para produzir glicoproteínas possuindo glicosilação de tipo humano
GB9902659D0 (en) 1999-02-05 1999-03-31 Microbiological Res Authority Assay with reduced background
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9906437D0 (en) 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU762857B2 (en) 1999-04-20 2003-07-10 Smithkline Beecham Biologicals (Sa) Vaccine
CO5241277A1 (es) 1999-04-20 2003-01-31 Glaxosmithkline Biolog Sa Vacuna
CA2370646A1 (en) 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization
US6706267B1 (en) 1999-09-14 2004-03-16 Arkion Life Sciences Llc Glucosamine and egg for reducing inflammation
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6537552B1 (en) 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EP1290019A2 (en) 2000-06-14 2003-03-12 Cytovax Biotechnologies Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
EP1946769B1 (en) 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
FR2816844A1 (fr) 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
FR2819724B1 (fr) 2001-01-22 2005-05-13 Inst Necker Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002347152A1 (en) 2001-12-05 2003-06-17 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US20030118591A1 (en) 2001-12-21 2003-06-26 Joshua Levy Passive hyperimmune antibody therapy in the treatment of anthrax
US7718375B2 (en) 2002-02-27 2010-05-18 Binax, Inc. Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children
US20030211110A1 (en) 2002-05-07 2003-11-13 Laniado Kiryat Sanz Hospital Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical epiosode of an incurable disease and methods of use thereof
WO2003094961A1 (en) 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
CN100443116C (zh) 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
WO2004052394A1 (en) 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
GB0301433D0 (en) 2003-01-22 2003-02-19 Adjuvantix Ltd Protein adjuvant
WO2004097000A2 (en) 2003-04-29 2004-11-11 Purdue Research Foundation Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
ES2317043T3 (es) 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
AU2004263135B2 (en) 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6984492B2 (en) 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
US20050070876A1 (en) 2003-09-26 2005-03-31 Penjet Corporation Method and apparatus for administering a vaccine or other pharmaceutical
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
US20090104220A1 (en) 2003-12-18 2009-04-23 Elisabetta Bianchi Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
WO2005065382A2 (en) 2003-12-31 2005-07-21 University Of Rochester Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005120563A2 (en) 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
CA2472818A1 (en) 2004-06-30 2005-12-30 Institut Pasteur Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications
US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1652859A1 (en) * 2004-11-02 2006-05-03 ZLB Behring AG Immunoglobulin fractions
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
US20080219960A1 (en) 2004-12-16 2008-09-11 Masja Nathalie Nierop Groot Novel Efficient Production Process for Capsular Polysaccharides of Pathogenic Grampositive Bacteria by Heterologous Expression and Secretion of Complex Polysaccharides in Non-Pathogenic, Non-Invasive Gram-Positive Bacteria
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2006079989A2 (en) 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
CA2597489A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070009542A1 (en) 2005-07-05 2007-01-11 Galit Levin Method and device for transdermal immunization
CN1899609A (zh) 2005-07-19 2007-01-24 复旦大学附属眼耳鼻喉科医院 肺炎球菌多糖蛋白偶联疫苗及其制备方法
US8354249B2 (en) 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
WO2007023386A2 (en) 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
JP2009510032A (ja) 2005-09-30 2009-03-12 リポクセン テクノロジーズ リミテッド 多糖抗原及びタンパク質アジュバントを含む多価リポソームワクチン組成物
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
WO2007052059A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CA2636983A1 (en) 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
US8852585B2 (en) 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
CN101024079B (zh) 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
KR101838938B1 (ko) 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0606856D0 (en) 2006-04-05 2006-05-17 Univ Leicester Vaccine compositions
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
KR101446238B1 (ko) 2006-08-07 2014-10-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법
US20110002962A1 (en) 2006-08-17 2011-01-06 The Uab Research Foundation Immunogenic PcpA Polypeptides and Uses Thereof
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8722055B2 (en) 2006-09-27 2014-05-13 St. Jude Children's Research Hospital Synthetic Streptococcus pneumoniae vaccine
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0703369D0 (en) 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
WO2008146164A2 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
CA2692069C (en) 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009036036A1 (en) 2007-09-10 2009-03-19 Nickerson Cheryl A Methods and compositions based on culturing microorganisms in low sedimental fluid shear conditions
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
WO2009106085A1 (en) 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
WO2009140236A2 (en) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
EP2293815A4 (en) 2008-05-22 2013-04-03 Childrens Medical Center SYNERGISTIC IMMUNOGENIC FUSION PROTEIN POLYSACCHARIDE CONJUGATE
US20100040601A1 (en) 2008-06-10 2010-02-18 Cantin Edouard M Compositions and methods for treating herpes simplex virus infections and related diseases
US20110236414A1 (en) 2008-08-08 2011-09-29 Intercell Ag Bacterial Polysaccharide-Polypeptide Conjugate Compositions
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
MX2011008799A (es) 2009-02-19 2011-09-27 Glaxo Group Ltd Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010109325A2 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
US8003112B2 (en) 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
WO2010132686A1 (en) 2009-05-13 2010-11-18 Gliknik, Inc. Methods of using immunoglobulin aggregates
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US20120100172A1 (en) 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
JP5931724B2 (ja) 2009-06-29 2016-06-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
CN101590224A (zh) 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
CA2773690A1 (en) 2009-09-09 2011-03-17 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
EP2482843A4 (en) 2009-10-02 2013-05-15 Univ Iowa Res Found PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
KR20110068831A (ko) 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
US20130209564A1 (en) 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
CN101785857B (zh) 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102068690A (zh) 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
US20130108619A1 (en) 2011-11-02 2013-05-02 Isaac Melamed Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
US11339206B2 (en) 2022-05-24
US20180086818A1 (en) 2018-03-29
AU2021202598B2 (en) 2024-09-19
US9969793B2 (en) 2018-05-15
US20220403008A1 (en) 2022-12-22
HK1225397A1 (en) 2017-09-08
BR102015027387A2 (pt) 2017-12-05
WO2016069693A1 (en) 2016-05-06
US20180258159A1 (en) 2018-09-13
AU2021202598A1 (en) 2021-05-27
EP4233903A2 (en) 2023-08-30
ZA201707303B (en) 2020-01-29
IL263819A (en) 2019-01-31
AU2015246157B2 (en) 2021-05-20
MX370191B (es) 2019-12-04
US20160115221A1 (en) 2016-04-28
EP4233903A3 (en) 2023-11-29
US9714283B2 (en) 2017-07-25
US20210130441A1 (en) 2021-05-06
AU2015246157A1 (en) 2016-05-12
US9107906B1 (en) 2015-08-18
US20240043503A1 (en) 2024-02-08
RU2015145033A3 (es) 2019-05-22
US9815886B2 (en) 2017-11-14
US10683343B2 (en) 2020-06-16
US20160114037A1 (en) 2016-04-28
US12473351B2 (en) 2025-11-18
IL242156B (en) 2019-01-31
CA2910491C (en) 2026-03-31
US11780906B2 (en) 2023-10-10
EP3026059A1 (en) 2016-06-01
IL263819B (en) 2021-02-28
RU2724058C2 (ru) 2020-06-19
CA2910491A1 (en) 2016-04-28
RU2015145033A (ru) 2017-05-03

Similar Documents

Publication Publication Date Title
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
MX2016016533A (es) Combinaciones inmunogenas.
CO2017013356A2 (es) Anticuerpos de factor xi
GEAP202115055A (en) Anti-cd27 antibodies
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
MX2015016627A (es) Vacuna para la malaria.
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX377506B (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
MX2014006248A (es) Anticuerpos nonoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs).
MX389474B (es) Dimetilfumarato y regimenes de vacunacion.
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).

Legal Events

Date Code Title Description
FG Grant or registration